查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
肝细胞癌症市场:KOL的洞察
市场调查报告书
商品编码
1770211

肝细胞癌症市场:KOL的洞察

KOL Insight - Hepatocellular Carcinoma
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2个工作天内

价格
简介目录

本报告深入分析了肝细胞癌 (HCC) 市场中现有及新兴的生物製剂和研发管线疗法。报告基于12位关键意见领袖的洞察，探讨了卡博替尼 (Cabometyx) 和 Styvarga 使用率的下降、赛默飞世尔 (Cyramza) 的微弱影响以及 Tebinbra/Tizveni 预计带来的有限影响。报告中也探讨了 Tecentriq + Avastin 合併疗法、Imfinzi + Imjudo 的用法，以及近期临床试验对 HCC 治疗模式的影响。您将全面了解影响治疗偏好的因素、新疗法面临的课题以及不断发展的治疗方案。

关键问题解答

  • KOL 如何使用 Tecentriq + Avastin 治疗 HCC？
  • IMbrave050 的数据是否改变了 Tecentriq 的辅助治疗？
  • Imfinzi + Imjudo 组合在目前的治疗方案中处于什么位置？
  • KOL 如何看待 Opdivo + Yervoy 在肝细胞癌第一线治疗中的作用？
  • 专家如何看待 LEAP-012 和 CheckMate-9DW 研究的结果？
  • IMbrave251 与 EMERALD-2 等研究如何塑造治疗格局？
  • KOL 目前如何使用 Lenvima、Stivarga、Cabometyx 和 Cyramza？
  • 专家对哪些在研肝细胞癌疗法最为期待？

领导品牌

  • TECENTRIQ(Atezolizumab)
  • Avastin(Bevacizumab)
  • imufinji(Durvalumab)
  • imujudo(Tremelimumab)
  • Opdivo(Nivolumab)
  • yaboi(Ipilimumab)
  • KEYTRUDA(Pembrolizumab)
  • LENVIMA(Lenvatinib)
  • suchibaga(Regorafenib)
  • 卡博替尼（卡博替尼）
  • 赛乐姆（雷莫芦单抗）
  • 替舒利珠单抗
  • 纳莫德诺松
  • 替拉戈单抗
  • 利莫尼利单抗
  • 布地加利单抗
  • 卡舒吉特舒格
  • 阿米札鲁胺

参加专家清单的一部分

  • 德州大学西南医学中心肝肿瘤学程主任、教授、肝病学负责人
  • 美国密西根州多学科肝肿瘤诊所主任、助理教授、活体肝臟移植医疗主任、移植计画负责人
  • 胃肠病学和肝病学系助理教授史丹佛大学医学院，加州
  • 西班牙巴塞隆纳大学巴塞隆纳诊所医院 ICMDM、IDIBAPS 巴塞隆纳诊所肝癌 (BCLC) 组肝病科肝病专家
  • 英国伦敦帝国学院外科和肿瘤学系临床科学家兼肿瘤顾问医生
  • 义大利博洛尼亚大学医学与外科教授

方法论

"治疗趋势" 报告透过对全球领先的关键意见领袖 (KOL) 进行深入访谈，就关键疾病领域的当前和未来治疗前景进行深入探讨。 KOL 是根据严格的筛选标准精心挑选出来的，这些标准包括全球声誉、临床专业知识以及在治疗领域的影响力。每次访谈都附有精心设计的讨论指南。这些指南由我们与 KOL 合作制定，并由行业专家进行同行评审，以确保所提出的问题全面且与当前市场动态相关。透过在每份报告发布后12个月的持续市场监测，我们及时为您提供来自关键意见领袖 (KOL) 的重要新闻事件、市场变化和市场发展动态的更新。

我们的报告有何特别之处？

FirstWord Reports 是值得信赖的行业领导者，专注于製药业，为生物製药专业人士和决策者提供详细且切实可行的洞察。我们深厚的行业知识使我们能够为您提供相关且有价值的洞察，帮助您掌握新兴趋势并有效应对复杂课题。凭藉广泛的研究以及来自领先专家和关键意见领袖的独立、公正的见解，我们的报告可提供您所需的准确性和可靠性。独家访问独家访谈和数据，以及持续的市场监测，确保您全面了解市场动态。我们的报告涵盖 40 多个动态疾病领域、包括 KOL 洞察和定量医生调查在内的医生情报以及行业专家对医疗事务、数位健康、销售和营销、市场准入和其他领域问题的看法，使您能够做出更明智的、数据驱动的决策，从而在快速变化的行业中保持竞争力。

简介目录

This report provides a detailed analysis of current and emerging biologic and pipeline therapies in the hepatocellular carcinoma (HCC) market. Based on insights from 12 key opinion leaders, it examines the declining use of Cabometyx and Stivarga, the minimal impact of Cyramza, and the limited disruption expected from Tevimbra/Tizveni. The report also explores the use of Tecentriq plus Avastin, the uptake of Imfinzi and Imjudo, and the implications of recent clinical trials on the HCC treatment paradigm. Gain a comprehensive understanding of the factors influencing treatment preferences, the challenges new therapies face, and the evolving treatment algorithms.

Key Questions Answered:

  • How do KOLs use Tecentriq plus Avastin in HCC treatment?
  • Has the IMbrave050 data changed Tecentriq's adjuvant use?
  • Where does Imfinzi plus Imjudo fit in the current treatment algorithm?
  • How do KOLs view Opdivo plus Yervoy for first-line HCC?
  • What is the expert take on LEAP-012 and CheckMate -9DW trial results?
  • How are trials like IMbrave251 and EMERALD-2 shaping the landscape?
  • How do KOLs use Lenvima, Stivarga, Cabometyx and Cyramza today?
  • Which pipeline therapies excite experts the most for HCC?

Key Brands:

  • Tecentriq (atezolizumab)
  • Avastin (bevacizumab)
  • Imfinzi (durvalumab)
  • Imjudo (tremelimumab)
  • Opdivo (nivolumab)
  • Yervoy (ipilimumab)
  • Keytruda (pembrolizumab)
  • Lenvima (lenvatinib)
  • Stivarga (regorafenib)
  • Cabometyx (cabozantinib)
  • Cyramza (ramucirumab)
  • tislelizumab
  • namodenoson
  • tiragolumab
  • livmoniplimab
  • budigalimab
  • casdozokitug
  • amezalpat

Partial List of Participating Experts:

  • Professor, Medical Director of the Liver Tumor Program and Chief of Hepatology, University of Texas Southwestern Medical Center, TX
  • Assistant Professor, Medical Director of the Multidisciplinary Liver Tumor Clinic and Medical Director of the Living Donor Liver Transplantation Program, Michigan, US
  • Assistant Professor in the Division of Gastroenterology and Hepatology at the School of Medicine, Stanford University, CA
  • Hepatologist at the Liver Unit, Barcelona Clinic Liver Cancer (BCLC) group, ICMDM, Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain
  • Clinician Scientist and Consultant Medical Oncologist, Department of Surgery and Cancer, Imperial College London, London, UK
  • Full Professor, Department of Medical and Surgical Sciences, University of Bologna, Italy

Methodology:

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.